-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
iNature Helicobacter pylori (H.
pylori) infection is considered to be the most important risk factor in the pathogenesis of gastric cancer
.
This study aimed to evaluate the long-term effects of H.
pylori eradication therapy on gastric cancer morbidity and mortality in high-risk populations
.
On March 28, 2022, Ye Weimin of Fujian Medical University and Chen Jianshun of Changle Center for Disease Control and Prevention published a joint communication online in Gastroenterology (IF=23) entitled "Effect of Helicobacter pylori Eradication on Gastric Cancer Prevention: Updated Report from a Randomized Controlled Trial with 26.
5 Years of Follow-up", a prospective, randomized, placebo-controlled trial conducted in July 1994 in a high-risk area in southern China
.
A total of 1630 asymptomatic H.
pylori-infected patients were randomly assigned to receive standard triple therapy (n=817) for H.
pylori eradication or placebo (n=813) and were followed through December 2020
.
The primary outcome was the incidence of gastric cancer, with total and cause-specific mortality as secondary outcomes
.
During 26.
5 years of follow-up, 21 participants (2.
57%) in the treatment group and 35 participants (4.
31%) in the placebo group were diagnosed with gastric cancer
.
Participants who received H.
pylori had a lower incidence of gastric cancer compared with the placebo group (hazard ratio [HR] = 0.
57, 95% confidence interval [CI]: 0.
33-0.
98)
.
Greater risk reduction was observed in patients without gastric precancer (HR=0.
37, 95%CI: 0.
15-0.
95) and in patients without dyspepsia symptoms at baseline (HR=0.
44, 95%CI: 0.
21-0.
94) for obvious
.
In addition, only 16 of the 625 subjects in the treatment group with successful H.
pylori eradication were found to have gastric cancers compared to the 32 cases of gastric cancer observed in the 527 participants with persistent H.
pylori infection in the placebo group (HR=0.
46, 95 %CI: 0.
26-0.
83)
.
However, there were no statistically significant differences in any mortality endpoint between the two groups
.
In conclusion, eradication of Helicobacter pylori may provide long-term protection against gastric cancer in high-risk groups, especially in infected individuals without gastric precancerous lesions at baseline
.
Gastric cancer is the fifth most common cancer and the third leading cause of cancer death globally, with the highest incidence in East Asia
.
Helicobacter pylori (H.
pylori) infection is thought to be the initial trigger of the Correa cascade, a widely accepted model of gastric carcinogenesis ranging from superficial gastritis (SG), chronic atrophic gastritis (CAG), intestinal Metaplasia (IM), dysplasia (DYS), adenocarcinoma
.
Epidemiological data suggest that Helicobacter pylori infection is associated with an approximately 3-fold increased risk of non-cardia gastric cancer
.
To date, a number of randomized controlled trials have evaluated the effect of H.
pylori eradication on gastric cancer prevention
.
However, differences in study population, sample size, duration of follow-up, and gastric mucosal status may lead to heterogeneity in results regarding magnitude of risk reduction, and even no favorable effects were found in some reports
.
The study was conducted in 1994 as a randomized, placebo-controlled trial in Changle, Fuzhou, an area with a high incidence of gastric cancer in southern China
.
The initial 7.
5-year follow-up report showed no significant difference in gastric cancer incidence among treated participants
.
The study now reports updated results with 26.
5 years of follow-up to assess the long-term impact of H.
pylori eradication on gastric cancer morbidity and mortality
.
A total of 1630 asymptomatic H.
pylori-infected patients were randomly assigned to receive standard triple therapy (n=817) to eradicate H.
pylori or placebo (n=813) and were followed until December 2020
.
The primary outcome was the incidence of gastric cancer, with total and cause-specific mortality as secondary outcomes
.
During 26.
5 years of follow-up, 21 participants (2.
57%) in the treatment group and 35 participants (4.
31%) in the placebo group were diagnosed with gastric cancer
.
Participants who received H.
pylori had a lower incidence of gastric cancer compared with the placebo group (hazard ratio [HR] = 0.
57, 95% confidence interval [CI]: 0.
33-0.
98)
.
Greater risk reduction was observed in patients without gastric precancer (HR=0.
37, 95%CI: 0.
15-0.
95) and in patients without dyspepsia symptoms at baseline (HR=0.
44, 95%CI: 0.
21-0.
94) for obvious
.
In addition, only 16 of the 625 subjects in the treatment group with successful H.
pylori eradication were found to have gastric cancers compared to the 32 cases of gastric cancer observed in the 527 participants with persistent H.
pylori infection in the placebo group (HR=0.
46, 95 %CI: 0.
26-0.
83)
.
However, there were no statistically significant differences in any mortality endpoint between the two groups
.
In conclusion, eradication of Helicobacter pylori may provide long-term protection against gastric cancer in high-risk groups, especially in infected individuals without gastric precancerous lesions at baseline
.
Reference news: https://#relatedArticles
pylori) infection is considered to be the most important risk factor in the pathogenesis of gastric cancer
.
This study aimed to evaluate the long-term effects of H.
pylori eradication therapy on gastric cancer morbidity and mortality in high-risk populations
.
On March 28, 2022, Ye Weimin of Fujian Medical University and Chen Jianshun of Changle Center for Disease Control and Prevention published a joint communication online in Gastroenterology (IF=23) entitled "Effect of Helicobacter pylori Eradication on Gastric Cancer Prevention: Updated Report from a Randomized Controlled Trial with 26.
5 Years of Follow-up", a prospective, randomized, placebo-controlled trial conducted in July 1994 in a high-risk area in southern China
.
A total of 1630 asymptomatic H.
pylori-infected patients were randomly assigned to receive standard triple therapy (n=817) for H.
pylori eradication or placebo (n=813) and were followed through December 2020
.
The primary outcome was the incidence of gastric cancer, with total and cause-specific mortality as secondary outcomes
.
During 26.
5 years of follow-up, 21 participants (2.
57%) in the treatment group and 35 participants (4.
31%) in the placebo group were diagnosed with gastric cancer
.
Participants who received H.
pylori had a lower incidence of gastric cancer compared with the placebo group (hazard ratio [HR] = 0.
57, 95% confidence interval [CI]: 0.
33-0.
98)
.
Greater risk reduction was observed in patients without gastric precancer (HR=0.
37, 95%CI: 0.
15-0.
95) and in patients without dyspepsia symptoms at baseline (HR=0.
44, 95%CI: 0.
21-0.
94) for obvious
.
In addition, only 16 of the 625 subjects in the treatment group with successful H.
pylori eradication were found to have gastric cancers compared to the 32 cases of gastric cancer observed in the 527 participants with persistent H.
pylori infection in the placebo group (HR=0.
46, 95 %CI: 0.
26-0.
83)
.
However, there were no statistically significant differences in any mortality endpoint between the two groups
.
In conclusion, eradication of Helicobacter pylori may provide long-term protection against gastric cancer in high-risk groups, especially in infected individuals without gastric precancerous lesions at baseline
.
Gastric cancer is the fifth most common cancer and the third leading cause of cancer death globally, with the highest incidence in East Asia
.
Helicobacter pylori (H.
pylori) infection is thought to be the initial trigger of the Correa cascade, a widely accepted model of gastric carcinogenesis ranging from superficial gastritis (SG), chronic atrophic gastritis (CAG), intestinal Metaplasia (IM), dysplasia (DYS), adenocarcinoma
.
Epidemiological data suggest that Helicobacter pylori infection is associated with an approximately 3-fold increased risk of non-cardia gastric cancer
.
To date, a number of randomized controlled trials have evaluated the effect of H.
pylori eradication on gastric cancer prevention
.
However, differences in study population, sample size, duration of follow-up, and gastric mucosal status may lead to heterogeneity in results regarding magnitude of risk reduction, and even no favorable effects were found in some reports
.
The study was conducted in 1994 as a randomized, placebo-controlled trial in Changle, Fuzhou, an area with a high incidence of gastric cancer in southern China
.
The initial 7.
5-year follow-up report showed no significant difference in gastric cancer incidence among treated participants
.
The study now reports updated results with 26.
5 years of follow-up to assess the long-term impact of H.
pylori eradication on gastric cancer morbidity and mortality
.
A total of 1630 asymptomatic H.
pylori-infected patients were randomly assigned to receive standard triple therapy (n=817) to eradicate H.
pylori or placebo (n=813) and were followed until December 2020
.
The primary outcome was the incidence of gastric cancer, with total and cause-specific mortality as secondary outcomes
.
During 26.
5 years of follow-up, 21 participants (2.
57%) in the treatment group and 35 participants (4.
31%) in the placebo group were diagnosed with gastric cancer
.
Participants who received H.
pylori had a lower incidence of gastric cancer compared with the placebo group (hazard ratio [HR] = 0.
57, 95% confidence interval [CI]: 0.
33-0.
98)
.
Greater risk reduction was observed in patients without gastric precancer (HR=0.
37, 95%CI: 0.
15-0.
95) and in patients without dyspepsia symptoms at baseline (HR=0.
44, 95%CI: 0.
21-0.
94) for obvious
.
In addition, only 16 of the 625 subjects in the treatment group with successful H.
pylori eradication were found to have gastric cancers compared to the 32 cases of gastric cancer observed in the 527 participants with persistent H.
pylori infection in the placebo group (HR=0.
46, 95 %CI: 0.
26-0.
83)
.
However, there were no statistically significant differences in any mortality endpoint between the two groups
.
In conclusion, eradication of Helicobacter pylori may provide long-term protection against gastric cancer in high-risk groups, especially in infected individuals without gastric precancerous lesions at baseline
.
Reference news: https://#relatedArticles
